Diyong Xu

Bio

Professional summary

Diyong Xu is a Partner on OrbiMed's Private Equity team and has been with the firm since 2012. Before OrbiMed, he was an investment banking analyst in Lazard's healthcare group, advising biotech, diagnostics and pharma clients on M&A, financing and strategic transactions. Public company and portfolio-company sources list him as a director of Q32 Bio, Frontera Therapeutics and Sirius Therapeutics.

Notable companies

Selected portfolio companies the partner has backed

Q32 BioFrontera TherapeuticsSirius TherapeuticsOnCusp Therapeutics

Background

Career, education, and skills

Career history

OrbiMedPartner, Private Equity2012 – Present
LazardInvestment Banking Analyst, Healthcare

Education

Stanford UniversityM.S. in Management Science and Engineering
Dartmouth CollegeM.S. in Molecular and Cellular Biology
Zhejiang UniversityB.S. in Biology

Other partners at OrbiMed

12 more profiles

View firm →

Aditya Tolia

Private Equity Senior Analyst

OrbiMed

Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.

Financial modelingHealthcare investingInvestment bankingM&APrivate equity

Alexis Megibow

Private Equity Associate

OrbiMed

Private Equity Associate at OrbiMed.

Healthcare investingPrivate equityVenture capital

Ankesh Bhansali

Managing Director

OrbiMed

OrbiMed Asia Managing Director focused on healthcare private equity.

Asia healthcareCapital marketsHealthcare deliveryHealthcare private equityM&APharmaceuticals

Arun Sadhanandham

Managing Director

OrbiMed

OrbiMed Asia Managing Director investing in healthcare private equity.

Asia healthcareHealthcare deliveryHealthcare private equityInvestment bankingMedical devicesPharmaceuticals

Brendan Weber, CFA

Principal

OrbiMed

Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.

Healthcare creditMedical devicesPharmaceuticalsRoyalty-based financingStructured credit

Carl Gordon

Managing Partner

OrbiMed

OrbiMed Managing Partner leading private equity and biotech company formation.

BiotechnologyBoard governanceCompany formationHealthcare private equityInnovative therapeuticsLife sciences

Carl L. Gordon

Managing Partner

OrbiMed

Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.

Life-sciences private equityTherapeuticsVenture investing

Carter Neild

Managing Partner

OrbiMed

OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.

Asia private investmentsHealthcare private equityHealthcare royaltiesInvestment managementStructured healthcare finance

Clay Daniel DeMarcus

Principal

OrbiMed

Principal focused on medical technology and non-therapeutics venture investing.

Healthcare equity researchHealthcare investment bankingMedical technologyNon-therapeuticsVenture-stage investing

Cooper Steputis

Private Equity / Venture Capital

OrbiMed

Healthcare private equity and venture investor with prior investment banking experience.

Healthcare venture capitalInvestment bankingMolecular biologyNeurosciencePrivate equity

Daniel Ying

Executive Director

OrbiMed

OrbiMed Asia Executive Director focused on pharma and biotech investments.

Asia healthcareBiotechnologyChina healthcare marketHealthcare private equityPharmaceuticals

David Bonita

General Partner

OrbiMed

OrbiMed General Partner and physician-investor in healthcare and therapeutics.

BiotechnologyBoard governanceHealthcare investingMedical devicesOncologyTherapeutics

See something out of date?

Suggest a correction — our team reviews every edit.

Improve this profile